Unicycive Therapeutics (UNCY) Price to Sales (2022 - 2023)
Unicycive Therapeutics' (UNCY) quarterly Price to Sales came in at 47.39 in Q1 2023, up 406.32% quarter-over-quarter from 9.36 in Q3 2022.
Powered by 
Analysis
Unicycive Therapeutics (UNCY) Price to Sales (2022 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has reported Price to Sales for 2 consecutive years, with 47.39 the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Price to Sales changed N/A year-over-year to 47.39; the trailing twelve-month figure through Dec 2023 stood at 31.54 (changed N/A YoY), and the FY2023 full-year result was 31.54, up 264.73% from the prior year.
- Price to Sales climbed to 47.39 in Q1 2023 per UNCY's latest filing, from 9.36 in the prior quarter.
- Across five years, Price to Sales topped out at 47.39 in Q1 2023 and bottomed at 9.36 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Unicycive Therapeutics | 143.47 Mn | 143.47 Mn | - |